In a phase II trial with GPC3 peptide vaccination for HCC, the vaccine reduced 1‐year recurrence by 15% and improved 5‐ and 8‐year survival rates by 10 and 30%, respectively. The gene discussed is GPC3; the disease is hepatocellular carcinoma.